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cell transplantation, recipient hematopoiesis is rapidly
replaced with donor-derived cells. Various approaches have
been used to measure the reconstitution of cellular and
humoral immunity, as it provides protection against infec-
tious pathogens and effects graft-versus-tumor (GVT) ac-
tivity. Indicators include restoration of absolute neutrophil
and lymphocyte counts; normalization of lymphocyte sub-
set distribution between naïve, memory, effector, and reg-
ulatory cells; emergence of recent thymic emigrants; and
detection of antigen-speciﬁc cellular immunity [1]. In
addition, diversity of the T cell repertoire has been
measured by spectratyping, an assay that measures the
breadth of utilization of individual TCR Vb genes [2].
Recognizing those aspects of reconstitution that correlate
with and are causative for clinical outcomes enables the
identiﬁcation of patients at high risk for infection and the
development of approaches to correct deﬁcient elements of
immune recovery.
Immune reconstitution is particularly important after
umbilical cord blood transplantation (UCBT), given the sig-
niﬁcant temporal delays in myeloid and lymphoid recovery
compared with after standard HLA-matched unrelated stem
cell transplantations [3,4]. Many variables have been found to
inﬂuence immune reconstitution after UCBT, including age of
recipient, baseline thymic activity, use of multiple umbilical
cord blood products, in vivo T cell depletion with alemtuzu-
mab or antithymocyte globulin, intensity of conditioning, and
graft-versus-host-disease (GVHD) prophylaxis. Nevertheless,
the relative delay in immune reconstitution is a consistent
observation after UCBT, and impaired recovery has been
correlated with increased incidence of infection and non-
relapse mortality (NRM).
In this issue, Saliba et al. present their analysis of nu-
merical and functional antigen-speciﬁc lymphocyte recon-
stitution after double cord blood transplantation (dUCBT)
[5]. One hundred eight adult patients who engrafted after
dUCBT were tracked for standard demographic and clinical
outcomes to identify predictors of 3-year NRM. Of note, all
patients received antithymocyte globulin in their prepara-
tive regimen and 70% received a cord blood product
expanded ex vivo after coculture with mesenchymalDOI of original article: http://dx.doi.org/10.1016/j.bbmt.2015.02.017.
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http://dx.doi.org/10.1016/j.bbmt.2015.04.027stromal cells. Multivariate analysis demonstrated that ab-
solute lymphocyte count (ALC) at 30 days above or below
150  106/L was strongly associated with NRM and survival.
In 65 recipients, immunophenotyping of peripheral blood
mononuclear cells after transplantation revealed early re-
covery of natural killer cells and B cells followed by delayed
recovery of CD4þ and CD8þ T cells with an inverted CD4/
CD8 T cell ratio. In a subset of 46 recipients, stimulation of
peripheral blood mononuclear cells with peptides repre-
senting immunogenic antigens from 6 viruses (cytomega-
lovirus, Epstein-Barr virus, BK virus, adenovirus, inﬂuenza,
and respiratory syncytial virus) was used to assess recovery
of speciﬁc T cell responses against these viral pathogens.
ELIspot assays demonstrated slow recovery of viral-speciﬁc
T cell activity until at least 9 months after dUCBT. Notably,
there was no correlation between normalization of ALC,
CD4, or CD8 T cell numbers and detection of viral-speciﬁc T
cell immunity. Nevertheless, a low ALC 30 days after
transplantation represents an easy, rapid way of identifying
patients at high risk for poor outcomes. Similar results have
been demonstrated in patients receiving ﬁlgrastim-
mobilized peripheral blood stem cell grafts [6]. Identiﬁca-
tion of these high-risk patients early after transplantation
can facilitate closer monitoring and early interventions to
mitigate serious infections.
The overarching conclusion of studies on immune
reconstitution has been that lack of diversity or skewing of
the T cell repertoire increases the risk of infections, NRM,
death, and potentially GVHD [7,8]. Adoptive therapy with
virus-speciﬁc T cells or other T cell populations expanded
ex vivo can provide protection against speciﬁc pathogens but
may not be sufﬁcient to robustly augment T cell repertoire
diversity. Achieving a truly diverse T cell population
will likely impact the balance between GVT and GVHD re-
sponses and determine long-term outcomes after UCBT.
Measurements of total and naive lymphocytes, viral-speciﬁc
T cells, and recent thymic emigrants after hematopoietic
stem cell transplantation (Figure 1A,B) are all surrogate
markers for T cell diversity.
It is now possible to quantify T cell repertoire diversity
by next-generation sequencing of PCR-ampliﬁed products
representing the highly polymorphic CDR3 regions of indi-
vidual T cells (Figure 1C) [9,10]. This approach can identify
individual TCR gene rearrangements in millions of T cells
and provides a direct measurement of the TCR Vb reper-
toire. It is also possible to track individual T cell clones in
serial samples and quantify their expansion or loss. In pre-
liminary studies, NRM and survival have been shown to
correlate with early T cell repertoire diversity after UCBT
[11,12]. This approach may provide a more comprehensive
proﬁle of immune reconstitution and, when combined with
sequencing of the TCRa chain, may predict immunity to
speciﬁc pathogens and enable antigen-discovery in patients
with GVHD or GVT.
With continued development and reﬁnement of this
approach, monitoring T cell diversity and speciﬁcity in this
Figure 1. Assessment of immune reconstitution after hematopoietic stem cell transplantation. (A) Schematic of relative numerical and functional reconstitution of
CD3 T cells and naïve T cells. Comparison of recovery after transplantation with peripheral blood stem cells (PBSC) versus umbilical cord blood (UCB). (B) Recovery of
thymic function measured by T cell receptor excision circles (TREC) or recent thymic emigrants (RTE). (C) Assessment of T cell repertoire diversity by high-throughput
sequencing. CDR3 regions of the TCRb gene are PCR ampliﬁed using primers speciﬁc for each Vb and Jb subunit. The absolute number of productive CDR3 sequences
for each Vb/Jb pairing is determined by DNA sequencing and plotted in a 3-dimensional graph. Results are shown for a sample with low/moderate diversity obtained 3
months after dUCBT (left) compared with a high diversity sample from a healthy donor (right).
S. Nikiforow, J. Ritz / Biol Blood Marrow Transplant 21 (2015) 1149e11521152detailed manner may be used to identify patients at high risk
for serious infections and to evaluate the results of future
therapies designed to enhance immune reconstitution.
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